Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + Chemotherapy in Pediatric Relapsed ALL/LL
NCT03792256Phase 1Completed
- Sponsor
- Children's Oncology Group
- Start
- Apr 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Children's Oncology Group. Primary endpoints: Frequency of Dose Limiting Toxicities at 32 days, Frequency of Adverse Events at 26 months and 5 more. Started Apr 2019; status: completed.
02
Drugs
palbociclib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT03792256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792256.